Safety and Efficacy of PEG-rhG-CSF for Neutropenia Prophylaxis in GI Cancer Patients

A prospective, single-center study of 43 gastrointestinal cancer patients receiving combination chemotherapy with oral agents, conducted between March 2022 and January 2023. The dataset, authored by Hui Wang, compares a treatment group receiving pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) to a control group, with endpoints including safety and incidence of chemotherapy-induced neutropenia.

Use Cases

• Compare adverse event rates between treatment and control groups based on the reported incidence of neutropenia, thrombocytopenia, and leukopenia.
• Analyze the efficacy of PEG-rhG-CSF as primary prophylaxis based on the reported incidence of grade ≥2 chemotherapy-induced neutropenia.
• Assess patient safety profiles for combination chemotherapy including oral agents based on the reported overall and grade ≥3 adverse events.

Strengths

• Data originates from a prospective, controlled clinical study with a defined protocol.
• Includes results for 43 patients who completed at least two treatment cycles, with 26 in the treatment group and 17 in the control group.
• Reports specific statistical comparisons (p-values) for key endpoints like neutropenia incidence.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The study is described as exploratory and non-randomized, which may limit the generalizability of findings.

Provenance

Source

figshare, author Hui Wang.

Collection Method

Data collected from a prospective, single-center, open-label, exploratory, non-randomized controlled clinical study.

Time Range

Patient screening and treatment occurred between March 2022 and January 2023.

Freshness

Last updated 2026-04-14 04:19:44; freshness should be verified.